Open Access
SHS Web Conf.
Volume 144, 2022
2022 International Conference on Science and Technology Ethics and Human Future (STEHF 2022)
Article Number 01006
Number of page(s) 5
Section Research on Bioethics and Medical Science and Technology Ethics
Published online 26 August 2022
  1. DeTure, M. A., & Dickson, D. W. (2019). The neuropathological diagnosis of Alzheimer’s disease. Molecular neurodegeneration, 14(1), 32. [CrossRef] [Google Scholar]
  2. Schultz C., Del Tredici K.H.B: Neuropathology of Alzheimer’s Disease. In Alzheimer’s Disease Current Clinical Neurology. Edited by R. R, B. R. Totowa, NJ: Humana Press; 2004. [Google Scholar]
  3. Daneman, R., & Prat, A. (2015). The blood-brain barrier. Cold Spring Harbor perspectives in biology, 7(1), a020412. [CrossRef] [Google Scholar]
  4. Pardridge WM. Treatment of Alzheimer’s Disease and Blood-Brain Barrier Drug Delivery. Pharmaceuticals (Basel). 2020 Nov 16;13(11):394. doi: 10.3390/ph13110394. PMID: 33207605; PMCID: PMC7697739. [CrossRef] [Google Scholar]
  5. Karthivashan G, Ganesan P, Park SY, Kim JS, Choi DK. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug Deliv. 2018 Nov;25(1):307-320. doi: 10.1080/10717544.2018.1428243. PMID: 29350055; PMCID: PMC6058502. [CrossRef] [Google Scholar]
  6. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release. 2016 Aug 10; 235:34-47. doi: 10.1016/j.jconrel.2016.05.044. Epub 2016 May 18. PMID: 27208862. [CrossRef] [Google Scholar]
  7. Kafa H, Wang JT, Rubio N, Venner K, Anderson G, Pach E, Ballesteros B, Preston JE, Abbott NJ, AlJamal KT. The interaction of carbon nanotubes with an in vitro blood-brain barrier model and mouse brain in vivo. Biomaterials. 2015;53:437-52. doi: 10.1016/j.biomaterials.2015.02.083. Epub 2015 Mar 19. PMID: 25890741; PMCID: PMC4407899. [CrossRef] [Google Scholar]
  8. Spuch C, Navarro C. Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer’s Disease and Parkinson’s Disease). J Drug Deliv. 2011;2011:469679. doi: 10.1155/2011/469679. Epub 2011 Dec 13. PMID: 22203906; PMCID: PMC3238398. [CrossRef] [Google Scholar]
  9. Ross C, Taylor M, Fullwood N, Allsop D. Liposome delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine. 2018 Dec 12;13:85078522. doi: 10.2147/IJN.S183117. PMID: 30587974; PMCID: PMC6296687. [CrossRef] [Google Scholar]
  10. Zheng X, Shao X, Zhang C, Tan Y, Liu Q, Wan X, Zhang Q, Xu S, Jiang X. Intranasal H102 PeptideLoaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease. Pharm Res. 2015 Dec;32(12):3837-49. doi: 10.1007/s11095-0151744-9. Epub 2015 Jun 26. PMID: 26113236. [CrossRef] [Google Scholar]
  11. Farlow MR, Somogyi M. Transdermal patches for the treatment of neurologic conditions in elderly patients: a review. Prim Care Companion CNS Disord. 2011;13(6):PCC.11r01149. doi: 10.4088/PCC.11r01149. PMID: 22454804; PMCID: PMC3304686. [Google Scholar]
  12. Siafaka PI, Bülbül EÖ, Mutlu G, Okur ME, Karantas ID, Okur NÜ. Transdermal Drug Delivery Systems and their Potential in Alzheimer’s Disease Management. CNS Neurol Disord Drug Targets. 2020;19(5):360-373. doi: 10.2174/1871527319666200618150046. PMID: 32552655. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.